A PYMNTS Company

J&J to sell wrist fracture surgical system for FTC approval of Synthes buy

By  |  June 11, 2012

To allow Johnson & Johnson (J&J)’s proposed acquisition of Synthes, the Federal Trade Commission is requiring J&J sell its system for surgically treating distal radius wrist fractures. The original deal would remove Synthes, J&J’s direct rival for volar distal radius (DVR) treatment systems, from a market that is highly concentrated. J&J and Synthes have a combined U.S. market share of over 70 percent. The FTC claimed that a merger would lead to price increases for a surgical system that is widely used for wrist trauma.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    J&J will sell its entire trauma portfolio, in addition to its DVR plating system, to Biomet.

    Full content: FTC Press Release

     

    Related content: Analyzing Medical Device Mergers

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.